Navigation Links
Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
Date:1/12/2009

clearances. Abbott and AMO expect the transaction to close in the first quarter of 2009.

Abbott Conference Call

Abbott will conduct a special conference call today at 8 a.m. Central time(9 a.m. Eastern time) to provide an overview of the transaction. The live Webcast will be accessible through Abbott's Investor Relations Web site at http://www.abbottinvestor.com.

About Advanced Medical Optics (AMO)

AMO is focused on providing the full range of advanced refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages. The company has operations in 27 countries and markets products in approximately 60 countries. For more information, visit the company's Web site at http://www.amo-inc.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

Additional Information

The tender offer described in this press release has not yet commenced, and this press release is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Abbott will file a tender offer statement with the U.S. Securities and Exchange Commission (SEC). Investors and AMO security holders are strongly advised to read the tender offer statement (including an offer to purchase, letter of trans
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Abbott Announces Earnings Guidance for 2009
2. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
3. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
4. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
5. Abbott Hosts Conference Call for Third-Quarter Earnings
6. Abbott to Present at UBS Best of Americas Investment Conference
7. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
8. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
9. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
10. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
11. Abbott Invests Additional $20M in Isis Subsidiary Ibis Biosciences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasd...ircuit Court of Appeals reversed a U.S. District C... pursue all of its claims against The Lash Group, ...ial. CTI filed a complaint against The Lash Group...t for CTI,s product TRISENOX, in 2007 seeking $22....
(Date:11/19/2009)...stCall/ -- Omeros Corporation (Nasdaq: OMER ) tod...hird quarter ended September 30, 2009. For the thr...d a net loss of $3.9 million, or $1.34 per share, ...4 per share, for the same period in 2008. For the ...reported a net loss of $15.5 million, or $5.29 per...
(Date:11/19/2009)...ss., Nov. 19 Arlington Medical Res...leading driver of antibiotic selection in nosocomi...against gram-positive and gram-negative pathogens....socomial pneumonia, surveyed European physicians r...vide appropriate coverage against common pathogens...
(Date:11/19/2009)...d by latest award for revolutionary hearing aid. ...ber 16, 2009 -- Popular Science Magazine has named...m InSound Medical a winner of its coveted Best of ...p;   Chosen from thousands of entra...ng canal for up to four months while providing nat...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...s, but it happens every year twice, in fact, as I...night was no exception. , ,After four months of i....m. deadline this morning to turn the raw ingredie...ram for 500-plus of DEMOs closest friends the inv...the event each year. , ,I dont go into the DEMO pr...
...has become is the first seed lab in the United Sta...ed Lab (ASL) program, administered by the United ...ny reported Tuesday. , , BioDiagnostics provides ...rvices. , ,The ASL Program is a voluntary, user-f... Seed testing laboratories, which meet all require...
...urer of diode lasers for industrial, defense, and ... $7 million in expansion funding, the company repo...d by GF Private Equity Group, LLC and included all...include ARCH Venture Partners, Advanced Technology...ture Investors, Wisconsin Alumni Research Foundati...
Other Biology Technology:DEMOfall - A return to simplicity 2DEMOfall - A return to simplicity 3Alfalight receives $7 million in expansion funding 2
(Date:11/20/2009)...entific and technological frontiers. The National ...hat totals nearly $4.3 million for the diverse eff...ican Recovery and Reinvestment Act of 2009. , ...stigation of solar phenomena. Philip R. Goode, dis...capabilities of NJIT,s Big Bear Solar Observatory ...
(Date:11/20/2009)...about the health benefits of having a life partner...here amino acids known as cysteines are much more ...up with other cysteines. , Now, researchers at t...n Belgium, have discovered a new antioxidant syste...ears in the Nov. 20 issue of the journal Science ...
(Date:11/20/2009)...ahoma researchers were sequencing the first human ...Today, the OU Advanced Center for Genome Technolog...quence the tomato genome with a $7.5 million grant...ant genomics. , "The tomato has tremendous agri...op yields will improve quality of life," said Bruc...
Breaking Biology News(10 mins):NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Saving the single cysteine: New antioxidant system found 2NSF awards $7.5M grant to University of Oklahoma for plant genomics 2PTC Therapeutics Receives 242 6 Million in Government Grants 12621 1PTC Therapeutics Receives 242 6 Million in Government Grants 12621 2PTC Therapeutics Receives 242 6 Million in Government Grants 12621 3PTC Therapeutics Receives 242 6 Million in Government Grants 12621 4Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 1Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 2Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 3Top Performing Medical Equipment Companies Announced 48860 1Top Performing Medical Equipment Companies Announced 48860 2
...ns, Inc. (NYSE: ID ), a leading provider of ident...t closed its tender offer for all of the,outstandi... and completed its,acquisition of Digimarc,s ID sy... period for the tender offer expired at,5:00 p.m. ...ubsequent,offering period, L-1 purchased 22,093,16...
...ncers are inherited, but the genetic cause of most...colorectal cancer account for less than 5 percent ...sity,s Feinberg School of Medicine and colleagues ... 10 to 20 percent of patients with colorectal canc...s a major contributor to colorectal cancer risk an...
... response to daily stress is the focus of a study ... of control. , "Research shows that two-thirds o...despite the best efforts of their doctors. That is...of the Georgia Prevention Institute at the Medical... the mechanisms through which blood pressure is re...
Other Biology News:L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation 2L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation 3Scientists discover major genetic cause of colorectal cancer 2Blood pressure response to daily stress provides clues for better hypertension treatment 2Blood pressure response to daily stress provides clues for better hypertension treatment 3Blood pressure response to daily stress provides clues for better hypertension treatment 4Blood pressure response to daily stress provides clues for better hypertension treatment 5Blood pressure response to daily stress provides clues for better hypertension treatment 6
Fluoroskan Ascent FL, 100-240 V from Thermo Scientific
Rabbit Anti-CHIP Polyclonal Antibody, Unconjugated from Abcam
Universal Adjustable Angle Test Tube Holder from Thermo Scientific
... Science, which pioneered the blending of thermost... and Expand Long Template PCR Systems, now introdu...irst product of a family of next-generation PCR Bl...with a novel proofreading protein isolated and cha...
Biology Products: